©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Coagulation Factor XIa Cleaves the RHDS Sequence and Abolishes the Cell Adhesive Properties of the Amyloid -Protein (*)

(Received for publication, August 17, 1995)

Susan M. Saporito-Irwin (§) William E. Van Nostrand (¶)

From the Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine, California 92717-4025

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Amyloid beta-protein (Abeta) is the major constituent of senile plaques and cerebrovascular amyloid deposits in Alzheimer's disease and is proteolytically derived from its transmembrane parent protein the amyloid beta-protein precursor (AbetaPP). Although the physiological role(s) of secreted AbetaPPs are not fully understood, several potential functions have been described including the regulation of hemostatic enzymes factors XIa and IXa and a role in cell adhesion. In the present study, we investigated the proteolytic processing of AbetaPP by factor XIa (FXIa). Incubation of the human glioblastoma cell line U138 stably transfected to overexpress the 695 isoform of AbetaPP with FXIa (2.5-5 nM) resulted in proteolytic cleavage of secreted AbetaPP. Higher concentrations of FXIa (>25 nM) resulted in loss in cell adherence. Coincubation of FXIa with purified, recombinant Kunitz protease inhibitor domain of AbetaPP blocked both the proteolytic processing of AbetaPP and the loss of cell adhesion. The RHDS cell adhesion site of AbetaPP resides within residues 5-8 of the Abeta domain. Incubation of synthetic Abeta peptide with increasing concentrations of FXIa resulted in cleavage of Abeta between Arg^5 and His^6 within the cell adhesion domain of the peptide. FXIa-digested Abeta or AbetaPP lost their abilities to serve as cell adhesion substrates consistent with cleavage through this cell adhesion site. Together, these results suggest a new potential biological function for FXIa in the modulation of cell adhesion. In addition, we have shown that FXIa can proteolytically alter Abeta and therefore possibly modify its physiological and perhaps pathological properties.


INTRODUCTION

Deposition of the amyloid beta-protein (Abeta) (^1)in senile plaques in the neuropil and in the walls of cerebral blood vessels is a pathologic feature of Alzheimer's disease. Abeta is a 39-42-amino acid protein that is proteolytically derived from its transmembrane parent protein, amyloid beta-protein precursor (AbetaPP)(1, 2, 3, 4) . AbetaPP is a multidomain protein that can be translated from alternatively spliced transcripts from a single gene located on chromosome 21(5, 6, 7, 8, 9, 10, 11) . The major mRNA species encode proteins of 695, 751, and 770 amino acids. The latter two isoforms contain a 56-amino acid domain that is homologous to Kunitz-type serine protease inhibitors (KPI)(9, 10, 11) . These isoforms are identical to the cell secreted inhibitor identified as protease nexin-2 (PN-2)(12, 13) . Secretory cleavage of AbetaPP occurs within the Abeta domain, and therefore, processing through this pathway precludes Abeta formation(14, 15) .

Although the physiological roles of secreted AbetaPP are not fully understood, several potential functions have been ascribed to it. For example, several laboratories have provided evidence that AbetaPP can mediate both cell-cell and cell-surface adhesion in neural and non-neural cells(16, 17, 18, 19, 20) . Recently, AbetaPP has been shown to be involved in regulating intracellular calcium levels in neurons, thus providing protection to these cells(21, 22) . Both the cell adhesion and neuroprotective activities have been localized to the carboxyl-terminal region of the secreted AbetaPP(17, 21, 22) . In addition, growth-promoting activities of AbetaPP in non-neural and neural cells have been reported(23, 24) . The region responsible for this autocrine activity has been identified as the sequence RERMS located in the middle portion of AbetaPP(24) .

Secreted forms of AbetaPP that contain the KPI domain have been shown to inhibit several different serine proteases, which include trypsin, chymotrypsin, and coagulation Factors XIa and IXa(12, 25, 26, 27, 28, 29) . Through inhibition of these latter two proteases, it has been suggested that the KPI-containing isoforms of AbetaPP may play a role in regulating hemostasis by acting as an anticoagulant(30) . Factor XIa (FXIa) participates in the middle phase of the intrinsic pathway of blood coagulation by converting the zymogen Factor IX to the active serine protease Factor IXa. Factor IXa then converts Factor X to Factor Xa, the next serine protease to participate in the coagulation cascade ultimately leading to fibrin clot formation(31) .

In the present study, we investigated the proteolytic processing of AbetaPP by FXIa. We report here that FXIa can cleave the RHDS sequence in the Abeta domain, altering the cell adhesive properties of both Abeta and secreted AbetaPP. These data suggest a new potential biological function for FXIa in the modulation of cell adhesion. These findings also indicate that the KPI domain of AbetaPP can regulate the activity of a protease that can process the Abeta domain, thus altering its potential physiological and pathological properties.


EXPERIMENTAL PROCEDURES

Materials

Purified human FXIa was purchased from Enzyme Research Laboratories. Purified alpha-thrombin (3554 units/mg) was purchased from Calbiochem. Dulbecco's modified Eagle's medium, fetal bovine serum, and Geneticin were obtained from Life Technologies, Inc. Abeta was synthesized and structurally characterized as described previously(32) . The recombinant KPI domain of AbetaPP was expressed and purified as described(33) . Purified secreted AbetaPP was prepared in a baculovirus system (34) and was kindly provided by Drs. L. Gregori and D. Goldgaber of the State University of New York at Stony Brook. The anti-PN-2/AbetaPP monoclonal antibody (mAb) P2-1 was prepared as previously reported(12) . mAb 6E10 to Abeta was a generous gift from Dr. K. S. Kim. Hybond nitrocellulose membranes, peroxidase-coupled secondary antibodies, and enhanced chemiluminescence reagents were purchased from Amersham Corp.

Cells

The human glioblastoma cell line U138 stably transfected to overexpress the 695-amino acid isoform of AbetaPP (U138/695) was generously provided by Dr. M. Murphy of the Salk Institute Biotechnology/Industrial Associates, Inc. These cells were routinely cultured in Dulbecco's modified Eagle's medium containing 2 mM glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, 100 µg/ml streptomycin sulfate, nonessential amino acids, 10% fetal bovine serum, and 20 µg/ml Geneticin.

Effects of Factor XIa on Proteolytic Processing of AbetaPP

U138/695 cells were grown to near confluency in 12-well tissue culture plates in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 20 µg/ml Geneticin as described above, rinsed one time with 1 ml of serum-free Dulbecco's modified Eagle's medium containing 0.1% bovine serum albumin, and then incubated in 1 ml of the same medium for 3 h. Then the medium was removed, replaced with 0.5 ml of serum-free medium alone or serum-free medium containing various concentrations of FXIa, and incubated for 18 h at 37 °C. In parallel experiments, cultures were treated with either 50 nM FXIa, 100 nM KPI, 50 nM FXIa, and 100 nM KPI or 100 nM thrombin for 18 h at 37 °C. The medium from control and treated cultures was collected, and the cells were solubilized as described previously(35) . All samples were stored at -30 °C until immunoblotting analysis.

Proteolytic Processing of Abeta by FXIa

Synthetic Abeta (25 µM) was incubated with increasing concentrations of FXIa for 24 h at 37 °C in serum-free medium. In a similar manner, Abeta was also treated with either 50 nM FXIa, 100 nM KPI, or 50 nM FXIa and 100 nM KPI. Aliquots of the digested peptide were analyzed by immunoblotting as described below.

Immunoblotting

For analysis of secreted and cellular AbetaPP proteins, aliquots of culture medium samples or cell lysate samples were separated by electrophoresis on nonreducing SDS 10% polyacrylamide gels(36) . For analysis of Abeta peptides, samples were electrophoresed on Tris/Tricine/SDS 10-20% gradient polyacrylamide gels. The proteins were then transferred onto Hybond membranes and probed using mAb P2-1 (5 µg/ml) or mAb 6E10 ascites (1:3000) for detection of AbetaPP or Abeta, respectively. Bound mouse monoclonal antibody was detected using a peroxidase-coupled sheep anti-mouse IgG (1:1000). Immunoreactivity was detected by enhanced chemiluminescence followed by exposure to Kodak X-Omat film.

Amino Acid Sequence Analysis

Synthetic Abeta (10 µg) was incubated with 100 nM FXIa at 37 °C for 24 h. An 3.4-kDa FXIa cleaved Abeta fragment was gel-purified by electrophoresis on a Tris/Tricine/SDS 10-20% polyacrylamide gel. The peptide was transferred to a polyvinylidene difluoride membrane and subjected to automated sequential Edman degradation analyses using on a 475A protein sequencer.

Cell Attachment Assay

35-mm plastic dishes were coated by evaporation overnight at 37 °C with the appropriate substrate diluted in 0.1 times phosphate-buffered saline. The substrates used were 2 µg Abeta; 400 ng FXIa; 65 ng KPI; 2 µg Abeta and 65 ng KPI; 400 ng FXIa and 65 ng KPI; 2 µg Abeta digested with 400 ng FXIa for 48 h at 37 °C; 2 µg Abeta digested with 400 ng FXIa then incubated with 65 ng KPI for 2 h at 37 °C; 10 µg of purified AbetaPP; 10 µg of AbetaPP digested with 200 ng of FXIa then incubated with 65 ng KPI for 2 h at 37 °C; and 10 µg of AbetaPP digested with 200 ng of thrombin. Exponentially dividing U138/695 cells were collected and suspended in serum-free medium. A 2-ml suspension containing 3.4 times 10^5 cells was pipetted into the coated dishes and incubated for 1 h at 37 °C. Nonadherent cells were removed by two gentle washes with serum-free culture medium. Adherent cells were then photographed using an Olympus phase contrast microscope. Cells were counted from 3-5 fields for each condition tested.


RESULTS

FXIa Induces Proteolytic Processing of Secreted AbetaPP in Cultured U138/695 Cells

We examined the effects of FXIa on AbetaPP processing in cultured U138/695 cells that have previously been shown to overproduce the AbetaPP isoform by 80-fold over untransfected glioblastoma cells(35) . Because AbetaPP lacks the KPI domain, the effects of FXIa could be tested without intrinsic inhibition by the PN-2 form of AbetaPP. Proteolytic processing of secreted AbetaPP was observed at 2.5 nM FXIa as evidenced by the appearance of a truncated secreted AbetaPP of 85 kDa in the culture media (Fig. 1A). At 50 nM FXIa, >90% of the secreted AbetaPP was cleaved. With higher concentrations of FXIa, additional cleavage sites were utilized as suggested by the appearance of additional smaller AbetaPP fragments. Cellular AbetaPP was not affected (data not shown).


Figure 1: Immunoblot analysis of secreted AbetaPP in cultured medium from U138/695 cells incubated with FXIa. A, near confluent cultures of U183/695 cells were incubated with increasing concentrations of FXIa for 18 h. The concentrations of FXIa used were: none (lane 1), 2.5 nM (lane 2), 5 nM (lane 3), 25 nM (lane 4), 50 nM (lane 5), 250 nM (lane 6), and 100 nM thrombin (lane 7). B, near confluent cultures of U138/695 cells were incubated alone (lane 1) or with 50 nM FXIa (lane 2), 50 nM FXIa and 100 nM KPI (lane 3), 100 nM KPI (lane 4), or 100 nM thrombin (lane 5) for 18 h. Aliquots of culture medium were analyzed for secreted AbetaPP by SDS-PAGE and subsequent immunoblotting with mAb P2-1 as described under ``Experimental Procedures.''



It was noted that the 85-kDa truncated secreted AbetaPP was very similar in size to that we and others have shown to be generated by thrombin proteolysis(35, 37, 38) . Therefore, we compared the effects of 50 nM FXIa and 100 nM thrombin on AbetaPP proteolysis in U138/695 cells (Fig. 1A). The amino acid sequence at the thrombin cleavage site in AbetaPP was determined to be EPR with cleavage occurring on the carboxyl side of the arginine residue(37) . This is the same sequence as the synthetic chromogenic substrate used to assay FXIa activity in vitro(39) . Based on sequence similarity and the size of the truncated secreted AbetaPP protein, the initial cleavage site utilized by FXIa is most likely the same as the thrombin cleavage site located at Arg-Ile of the AbetaPP sequence. FXIa cleavage of secreted AbetaPP could be inhibited when FXIa was preincubated with 100 nM KPI (Fig. 1B).

Factor XIa Alters Cell Adhesion of U138/695 Cells

In the course of studying the effects of increasing concentrations of FXIa on the proteolytic processing of AbetaPP, we observed that the cells lost adherence after 18 h when treated with 5-25 nM FXIa. Many of the cells that remained were rounded and no longer showed their characteristic elongated morphology. After an 18-h incubation with 50 nM FXIa, less than 20% of the cells remained adhered to the culture dish (Fig. 2B). In parallel experiments, similar concentrations of thrombin (Fig. 2E) and coagulation Factors IXa and Xa (data not shown) had no effect on cell adhesion. In addition, these effects of FXIa treatment could be inhibited by the addition of 100 nM KPI to the FXIa prior to incubation with the cells (Fig. 2D). Similar but less robust losses in cell adhesion were observed in the untransfected parent glioblastoma cell line, a neuroblastoma cell line, and cultured cerebrovascular smooth muscle cells (data not shown).


Figure 2: Effect of FXIa on cell adhesion of U138/695 cells. U138/695 cells were grown to 50% confluency, incubated for 18 h alone (A) or with 50 nM FXIa (B), 100 nM KPI (C), 50 nM FXIa and 100 nM KPI (D), or 100 nM thrombin (E), and then photographed using phase contrast microscopy. Magnification, times40.



FXIa Cleaves the Cell Adhesion RHDS Sequence of Abeta

A cell adhesion domain has been localized to the RHDS sequence of the Abeta domain located at the carboxyl terminus of secreted AbetaPP(18) . To determine if disruption of this domain by FXIa was responsible for the loss of adherence observed in the FXIa treated U138/695 cells, we examined the effect of FXIa on a synthetic Abeta peptide. With increasing FXIa concentrations, we detected a decrease in Abeta immunoreactivity using mAb 6E10 (Fig. 3A). At 50 nM FXIa, >80% of Abeta immunoreactivity was lost. In parallel experiments, neither thrombin nor KPI-treated FXIa had any effect on Abeta immunoreactivity (Fig. 3B).


Figure 3: Immunoblot analysis of Abeta incubated with FXIa. A, purified Abeta (25 µM) was incubated with increasing concentrations of FXIa for 24 h. The concentrations of FXIa used were: none (lane 1), 2.5 nM (lane 2), 5 nM (lane 3), 25 nM (lane 4), 50 nM (lane 5), and 250 nM (lane 6). B, purified Abeta (25 µM) was incubated alone (lane 1) or with 50 nM FXIa (lane 2), 50 nM FXIa and 100 nM KPI (lane 3), 100 nM KPI (lane 4), or 100 nM thrombin (lane 5) for 24 h. Aliquots of the incubation mix were analyzed for Abeta immunoreactivity by SDS-PAGE and subsequent immunoblotting with mAb 6E10 as described under ``Experimental Procedures.''



To further identify the site of FXIa cleavage within Abeta, 10 µg of the peptide was digested with 100 nM FXIa for 48 h. The digested peptide was analyzed on a Tris/Tricine/SDS 10-20% polyacrylamide gel. The Coomassie-stained gel revealed a truncated 3.4-kDa Abeta fragment (Fig. 4). In parallel experiments, the truncated Abeta peptide was transferred to a polyvinylidene difluoride membrane and subjected to amino-terminal sequence analysis. The resulting sequence derived from five cycles of sequential Edman degradation is shown in Table 1. The amino-terminal sequence of the truncated Abeta peptide identified the FXIa cleavage between Arg^5-His^6 within the RHDS cell adhesion domain.


Figure 4: SDS-PAGE analysis of Abeta digested with FXIa. Purified Abeta (10 µg) was incubated alone (lane 1) or with 100 nM FXIa (lane 2) at 37 °C for 24 h. The samples were analyzed by SDS-PAGE followed by staining with Coomassie Brilliant Blue.





FXIa Cleavage of the RHDS Sequence Abolishes the Cell Adhesion Properties of Abeta and Secreted AbetaPP

To determine if FXIa cleavage of the RHDS sequence disrupts the ability of Abeta to promote cell adhesion, we compared untreated and FXIa-digested Abeta as substrates in cell-surface adhesion. The U138/695 cells showed enhanced binding to the plastic culture dish treated with Abeta by nearly 20-fold over cells plated on 0.1 times phosphate-buffered saline-treated plastic dishes (Fig. 5A). However, when FXIa-digested Abeta was used as a substrate, cell adherence was abolished (Fig. 5A). In control experiments, the numbers of cells adhered to FXIa, KPI, or FXIa and KPI closely resembled the numbers of cells on phosphate-buffered saline-treated plastic (Fig. 5A). Similar to Abeta, cells adhered to purified AbetaPP but not FXIa-digested AbetaPP (Fig. 5B). It is noteworthy that cells adhered to thrombin-digested AbetaPP (Fig. 5B), consistent with a lack of Abeta cleavage by thrombin (Fig. 3B). No significant differences in numbers of adhered cells using fibronectin or FXIa-treated fibronectin were observed in parallel experiments (data not shown).


Figure 5: Effects of FXIa on the ability of Abeta and AbetaPP to promote cell adhesion of U138/695 cells. A suspension of U138/695 cells (3.4 times 10^5) in serum-free culture medium were incubated at 37 °C for 1 h on 35-mm plastic dishes coated with (A) nothing (lane 1), 400 ng FXIa (lane 2), 65 ng KPI (lane 3), 400 ng FXIa and 65 ng KPI (lane 4), 2 µg Abeta (lane 5), 2 µg Abeta and 65 ng KPI (lane 6), 2 µg Abeta digested with 400 ng FXIa (lane 7), or 2 µg Abeta digested with 400 ng FXIa then incubated with 65 ng KPI (lane 8) or coated with (B) 10 µg of AbetaPP (lane 1), 10 µg of AbetaPP digested with 200 ng of FXIa (lane 2), or 10 µg of AbetaPP digested with 200 ng of thrombin (lane 3). Nonadherent cells were removed as described under ``Experimental Procedures.'' Values are presented as the means ± S.D. percentage of adherent cells counted in 3-5 fields of view compared with Abeta or AbetaPP.




DISCUSSION

The present studies show that FXIa, a target protease for inhibition by the KPI domain of AbetaPP, proteolytically cleaves secreted AbetaPP from U138/695 cells. Initial cleavage at low FXIa concentrations (2.5 nM) occurred at the site previously reported for thrombin cleavage at Arg-Ile of AbetaPP. It is noteworthy that the amino acid sequence at the thrombin cleavage site in AbetaPP is Glu-Pro-Arg, the same sequence as the synthetic chromogenic substrate used to assay FXIa activity in vitro(39) . Additional cleavage sites were utilized at higher concentrations of FXIa (Fig. 1A). Several potential functions have been ascribed to secreted AbetaPP, including cell adhesion, growth supportive activity, and neuroprotection(16, 17, 18, 19, 20, 21, 22, 23, 24) . Proteolytic processing of AbetaPP by FXIa may disrupt one or more of these properties.

Reduced cell adhesion to the substratum was observed in FXIa-treated U138/695 cells. This may have resulted from disruption of the cell adhesion domain by FXIa. A cell adhesion site in AbetaPP has been localized within the amino-terminal region of the Abeta domain, which is present in secreted forms of the protein(18) . To test this hypothesis, synthetic Abeta was digested with increasing concentrations of FXIa. The loss of Abeta immunoreactivity observed in Fig. 3was consistent with disruption of the mAb 6E10 epitope, which has been mapped within the amino-terminal region of Abeta(40) . Accompanying the loss of Abeta immunoreactivity, we observed the appearance of a truncated Abeta peptide when treated with FXIa (Fig. 4). Amino-terminal sequence analysis of the first five amino acids of this truncated peptide yielded the Abeta sequence HDSGY (Table 1), consistent with cleavage through the cell adhesion domain RHDS. It is noteworthy that the RHDS cleavage site in the Abeta domain shows homology to the factor IX activation site for FXIa(32) . Because cleavage through the RHDS sequence may disrupt the cell adhesive properties of the Abeta domain, we compared the abilities of Abeta and FXIa-cleaved Abeta to serve as cell adhesion substrates. Abeta promoted adhesion of U138/695 cells to the substratum by nearly 20-fold over buffer-treated substratum (Fig. 5). However, FXIa-cleaved Abeta lost its ability to serve as cell adhesive substrate. Similarly, FXIa diminished the ability of secreted AbetaPP to promote cell adhesion. These results suggest that FXIa could disrupt adhesion of cells that may use this region of the Abeta domain as an extracellular matrix protein.

Together, these findings have identified a new potential function for FXIa in the modulation of cell adhesion. This suggests that in addition to a function in coagulation, FXIa may participate in other roles of wound repair and tissue remodeling at sites of vascular injury. It is noteworthy that platelets activated by physiological agonists release large amounts of PN-2/AbetaPP(27, 41) . Therefore, PN-2/AbetaPP released by platelets at sites of vascular damage may participate in both the regulation of coagulation and cell adhesion. Through its intimate interactions with PN-2/AbetaPP, FXIa may also be involved in both of these processes. The present data also show that the KPI domain of PN-2/AbetaPP can regulate the activity of a target protease that possesses the ability to modulate another potential biological function on a distal region of the protein. Moreover, these findings demonstrate that the KPI domain of PN-2/AbetaPP can regulate the activity of a protease that can cleave the Abeta peptide. Proteolytic processing of this nature could alter possible physiologic and perhaps pathologic properties of Abeta.


FOOTNOTES

*
This work was supported by Grant HL49566 and Research Career Development Award HL03229 (to W. E. V. N.) from the National Institutes of Health and Grant-in-Aid 94006240 from the American Heart Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by National Institute on Aging National Research Service Award AG00096-12 from the University of California, Irvine.

To whom correspondence should be addressed. Tel.: 714-824-2556; Fax: 714-824-8598.

(^1)
The abbreviations used are: Abeta, amyloid beta-protein; AbetaPP, amyloid beta-protein precursor; KPI, Kunitz protease inhibitor; PN-2, protease nexin-2; FXIa, factor XIa; mAb, monoclonal antibody; U138/695 cells, human glioblastoma U138 cells stably transfected to overexpress the AbetaPP isoform; PAGE, polyacrylamide gel electrophoresis.


REFERENCES

  1. Glenner, G. G., and Wong, C. W. (1984) Biochem. Biophys. Res. Commun. 120, 885-890 [Medline] [Order article via Infotrieve]
  2. Glenner, G. G., and Wong, C. W. (1984) Biochem. Biophys. Res. Commun. 122, 1131-1135 [Medline] [Order article via Infotrieve]
  3. Masters, C. L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R. N., and Beyreuther, K. (1985) EMBO J. 4, 2757-2763 [Abstract]
  4. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 4245-4269 [Abstract]
  5. Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) Nature 325, 733-736 [CrossRef][Medline] [Order article via Infotrieve]
  6. Goldgaber, D., Lerman. M. I., McBride, O. W., Saffiotti, U., and Gajdusek, D. C. (1987) Science 235, 877-880 [Medline] [Order article via Infotrieve]
  7. Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St. George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., and Neve, R. L. (1987) Science 235, 880-884 [Medline] [Order article via Infotrieve]
  8. Robakis, N. K., Ramakrishna, N., Wolfe, G., and Wisniewski, H. M. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4190-4194 [Abstract]
  9. Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., Fuller, F., and Cordell, B. (1988) Nature 331, 525-527 [CrossRef][Medline] [Order article via Infotrieve]
  10. Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., and Neve, R. L. (1988) Nature 331, 528-530 [CrossRef][Medline] [Order article via Infotrieve]
  11. Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S., and Ito, H. (1988) Nature 331, 530-532 [CrossRef][Medline] [Order article via Infotrieve]
  12. Van Nostrand, W. E., Wagner, S. L., Suzuki, M., Choi, B. H., Farrow, J. S., Geddes, J. W., Cotman, C. W., and Cunningham, D. D. (1989) Nature 341, 546-549 [CrossRef][Medline] [Order article via Infotrieve]
  13. Oltersdorf, T., Fritz, L. C., Schenk, D. B., Lieberburg, I., Johnson-Wood, K. L., Beattie, E. C., Ward, P. J., Blacher, R. W., Dovey, H. F., and Sinha, S. (1989) Nature 341, 144-147 [CrossRef][Medline] [Order article via Infotrieve]
  14. Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., and Ward, P. J. (1990) Science 248, 1122-1124 [Medline] [Order article via Infotrieve]
  15. Wang, R., Meschia, J. F., Cotter, R. J., and Sisodia, S. S. (1991) J. Biol. Chem. 266, 16960-16964 [Abstract/Free Full Text]
  16. Schubert, D., Jin, L.-W., Saitoh, T., and Cole, G. (1989) Neuron 3, 689-694 [Medline] [Order article via Infotrieve]
  17. Chen, M., and Yankner, B. A. (1991) Neurosci. Lett. 125, 223-226 [Medline] [Order article via Infotrieve]
  18. Ghiso, J., Rostagno, A., Gardella, J. E., Liem, L., Gorevic, P. D., and Frangione, B. (1992) Biochem. J. 288, 1053-1059 [Medline] [Order article via Infotrieve]
  19. Breen, K. C., Bruce, M., and Anderton, B. H. (1991) J. Neurosci. Res. 28, 90-100 [Medline] [Order article via Infotrieve]
  20. Klier, F. G., Cole, G., Stallcup, W., and Schubert, D. (1990) Brain Res. 515, 336-342 [Medline] [Order article via Infotrieve]
  21. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., and Rydell, R. E. (1993) Neuron 10, 243-254 [Medline] [Order article via Infotrieve]
  22. Mattson, M. P., Barger, S. W., Cheng, B., Lieberburg, I., Smith-Swintosky, V. L., Rydel, R. E. (1993) Trends Neurosci. 16, 409-414 [CrossRef][Medline] [Order article via Infotrieve]
  23. Saitoh, T., Sundsmo, M., Roch, J.-M., Kimura, N., Cole, G., Schubert, D., Oltersdorf, T., and Schenk, D. B. (1989) Cell 58, 615-622 [Medline] [Order article via Infotrieve]
  24. Ninomya, H., Roch, J.-M., Sundsumo, M. P., Otero, D. A. C., and Saitoh, T. (1993) J. Cell Biol. 121, 879-886 [Abstract]
  25. Van Nostrand, W. E., and Cunningham, D. D. (1987) J. Biol. Chem. 262, 8508-8514 [Abstract/Free Full Text]
  26. Van Nostrand, W. E., Wagner, S. L., Farrow, J. S., and Cunningham, D. D. (1990) J. Biol. Chem. 265, 9591-9594 [Abstract/Free Full Text]
  27. Smith, R. P., Higuchi, D. A., and Broze, G. J., Jr. (1990) Science 248, 1126-1128 [Medline] [Order article via Infotrieve]
  28. Schmaier, A. H., Dahl, L. D., Rozemuller, A. J. M., Roos, R. A. C., Wagner, S. L., Chung, R., and Van Nostrand, W. E. (1993) J. Clin. Invest. 92, 2540-2545 [Medline] [Order article via Infotrieve]
  29. Schmaier, A. H., Dahl, L. D., Hasan, A. A. K., Cines, D. B., Bauer, K. A., and Van Nostrand, W. E. (1995) Biochemistry 34, 1171-1178 [Medline] [Order article via Infotrieve]
  30. Van Nostrand, W. E., Schmaier, A. H., and Wagner, S. L. (1992) Ann. N. Y. Acad. Sci. 674, 243-52 [Abstract]
  31. Di Scipio, R. G., Kurachi, K., and Davie, E. W. (1978) J. Clin. Invest. 61, 1528-1538 [Medline] [Order article via Infotrieve]
  32. Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henscher, A., Yates, J., Cotman, C., and Glabe, C. (1992) J. Biol. Chem. 267, 546-554 [Abstract/Free Full Text]
  33. Wagner, S. L., Siegel, R. S., Vedvick, T., Raschke, W. C., and Van Nostrand, W. E. (1992) Biochem. Biophys. Res. Commun. 186, 1138-1145 [Medline] [Order article via Infotrieve]
  34. Bhasin, R., Van Nostrand, W. E., Saitoh, T., Donets, M. A., Barnes, E. A., Quitschke, W. W., and Goldgaber, D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10307-10311 [Abstract]
  35. Davis-Salinas, J., Saporito-Irwin, S. M., Donovan, F. M., Cunningham, D. D., and Van Nostrand, W. E. (1994) J. Biol. Chem. 269, 22623-22627 [Abstract/Free Full Text]
  36. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  37. Igarashi, K., Murai, H., and Asaka, J. (1992) Biochem. Biophys. Res. Commun. 185, 1000-1004 [Medline] [Order article via Infotrieve]
  38. Smith, R. P., and Broze, G. J. (1992) Blood 80, 2252-2260 [Abstract]
  39. van der Graaf, F., Greengard, J. S., Bouma, B. N., Kerbiriou, D. M., and Griffin, J. H. (1983) J. Biol. Chem. 258, 9669-9675 [Abstract/Free Full Text]
  40. Kim, K. S., Miller, D. L., Sapienza, V. J., Chen, C. M. J., Bai, C., Grundke-Iqbal, I., Currie, J. R., and Wisniewski, H. M. (1988) Neurosci. Res. Commun. 2, 121-130
  41. Van Nostrand, W. E., Schmaier, A. H., Farrow, J. S., and Cunningham, D. D. (1990) Science 248, 745-748 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.